| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(19)30656-4 |
| P698 | PubMed publication ID | 31797795 |
| P50 | author | Alexander Eggermont | Q28317101 |
| Carolyn Gotay | Q85655863 | ||
| Jaap C Reijneveld | Q93118855 | ||
| Galina Velikova | Q43195309 | ||
| P2093 | author name string | Andrew Bottomley | |
| Mogens Groenvold | |||
| Corneel Coens | |||
| Francesca Martinelli | |||
| Kristin Bjordal | |||
| Madeline Pe | |||
| Murielle Mauer | |||
| Claire Piccinin | |||
| Justyna Mierzynska | |||
| P2860 | cites work | Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement | Q21195843 |
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q27860647 | ||
| Taking patient reported outcomes centre stage in cancer research - why has it taken so long? | Q59883116 | ||
| Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines | Q90310964 | ||
| The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials | Q92774146 | ||
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study | Q30422170 | ||
| Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT | Q30671538 | ||
| PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force | Q30843066 | ||
| The Prognostic Value of Patient-Reported Outcome Data in Patients With Colorectal Hepatic Metastases Who Underwent Surgery | Q30991630 | ||
| The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group s | Q31117641 | ||
| Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards | Q31138363 | ||
| Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study | Q33311103 | ||
| Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials | Q33495456 | ||
| Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer | Q33587884 | ||
| Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation | Q33596402 | ||
| Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. | Q33613709 | ||
| Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study | Q33645784 | ||
| Quality of life assessment as a predictor of survival in non-small cell lung cancer | Q33993427 | ||
| Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer | Q34196497 | ||
| Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy | Q34344188 | ||
| Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial | Q34646032 | ||
| Relationship between deficits in overall quality of life and non-small-cell lung cancer survival | Q36058286 | ||
| Decline in physical functioning in first 2 years after breast cancer diagnosis predicts 10-year survival in older women | Q36599233 | ||
| Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial | Q36673860 | ||
| Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. | Q36728245 | ||
| Prevalence of pain in patients with cancer: a systematic review of the past 40 years | Q36758835 | ||
| Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303) | Q36856220 | ||
| Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma | Q36969519 | ||
| The prognostic significance of patient-reported outcomes in cancer clinical trials | Q37070024 | ||
| Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial | Q37126921 | ||
| Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. | Q37474276 | ||
| Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension | Q38084855 | ||
| Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials | Q38183571 | ||
| Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient | Q38548372 | ||
| Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study | Q38661788 | ||
| Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. | Q38736093 | ||
| Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials | Q38891401 | ||
| Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Ra | Q39302912 | ||
| Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RT | Q39302927 | ||
| The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients | Q39442334 | ||
| Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. | Q40090587 | ||
| Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. | Q40196022 | ||
| Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology | Q40265230 | ||
| Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study | Q40273166 | ||
| The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis. | Q40670403 | ||
| Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin | Q43436700 | ||
| Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma | Q43577790 | ||
| Pretreatment quality of life as a predictor of distant metastasis and survival for patients with nasopharyngeal carcinoma | Q44331881 | ||
| Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy | Q44665743 | ||
| Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Researc | Q44849766 | ||
| Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study | Q45233378 | ||
| Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials | Q45283698 | ||
| Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy | Q46066022 | ||
| Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pl | Q46843399 | ||
| The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies | Q47548951 | ||
| Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer | Q47553246 | ||
| Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. | Q47663349 | ||
| Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms | Q47858702 | ||
| Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation | Q48025129 | ||
| Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab i | Q48052421 | ||
| EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer | Q48084672 | ||
| Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. | Q48145007 | ||
| The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma | Q48349274 | ||
| Health-related quality of life and inflammatory markers in malignant pleural mesothelioma | Q48394328 | ||
| Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study | Q48487553 | ||
| Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension | Q48504041 | ||
| European Society for Medical Oncology (ESMO) position paper on supportive and palliative care | Q49668823 | ||
| Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma | Q50056316 | ||
| Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. | Q50897397 | ||
| Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. | Q53051521 | ||
| Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. | Q53104572 | ||
| The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. | Q53173828 | ||
| Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients. | Q53187063 | ||
| Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. | Q54141723 | ||
| The EORTC CAT Core—The computer adaptive version of the EORTC QLQ-C30 questionnaire | Q59882654 | ||
| P433 | issue | 12 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | e685-e698 | |
| P577 | publication date | 2019-12-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review | |
| P478 | volume | 20 |
| Q101558795 | Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer |
| Q95836457 | Effectiveness of Clinical Examination in Cancer Surveillance: New Paradigm to Cancer Survivorship Beyond the COVID-19 Pandemic |
| Q99413028 | Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study |
Search more.